CONNECTICUT, CT — The state Attorney General led a coalition of 51 states and territories Wednesday in filing the third lawsuit stemming from the ongoing antitrust investigation involving generic drug manufacturers.
The suit alleges the manufacturers engaged in a conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States.
This new complaint focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States. The suit names 26 corporate defendants and 10 individual defendants. The lawsuit seeks damages, civil penalties, and actions by the court to restore competition to the generic drug market.
The topical drugs at the center of the complaint include creams, gels, lotions, ointments, shampoos, and solutions used to treat a variety of skin conditions and allergies.
"These generic drug manufacturers perpetrated a multibillion-dollar fraud on the American public so systemic that it has touched nearly every single consumer of topical products," Connecticut Attorney General William Tong said in a statement. "Through phone calls, text messages, emails, corporate conventions, and cozy dinner parties, generic pharmaceutical executives were in constant communication, colluding to fix prices and restrain competition as though it were a standard course of business."
According to a news release from Tong's office, the complaint stems from an ongoing investigation built on evidence from several cooperating witnesses, a document database of over 20 million documents, and a phone records database containing millions of call detail records and contact information for over 600 sales and pricing individuals in the generics industry.
"They knew what they were doing was wrong, and they took steps to evade accountability, using code words and warning each other to avoid email and detection," Tong said. "Our case is built on hard evidence from multiple cooperating witnesses, millions of records, and contemporaneous notes that paint an undeniable picture of the largest domestic corporate cartel in our nation’s history."
Among the records obtained by the states is a two-volume notebook containing the notes of one of the states' cooperators that memorialized his discussions during phone calls with competitors and internal company meetings over a period of several years.
Between 2007 and 2014, three generic drug manufacturers, Taro, Perrigo, and Fougera (now Sandoz) sold nearly two-thirds of all generic topical products dispensed in the United States, according to the news release.
"The multistate investigation has uncovered comprehensive, direct evidence of unlawful agreements to minimize competition and raise prices on dozens of topical products," Tong said. "The Complaint alleges longstanding agreements among manufacturers to ensure a 'fair share' of the market for each competitor, and to prevent 'price erosion' due to competition."
The suit is the third to be filed in an ongoing, expanding investigation that the A.G.'s Office has referred to as "possibly the largest domestic corporate cartel case in the history of the United States."
The first Complaint, still pending in the U.S. District Court in the Eastern District of Pennsylvania, was filed in 2016 and now includes 18 corporate defendants, two individual defendants, and 15 generic drugs. Two former executives from Heritage Pharmaceuticals, Jeffery Glazer and Jason Malek, have entered into settlement agreements and are cooperating with the Attorneys General working group in that case. The second Complaint, also pending in the U.S. District Court in the Eastern District of Pennsylvania, was filed in 2019 against Teva Pharmaceuticals and 19 of the nation’s largest generic drug manufacturers. The Complaint names 16 individual senior executive defendants. The States are currently preparing for trial on that complaint.
Corporate Defendants:
Sandoz, Inc.
Actavis Holdco U.S., Inc.
Actavis Elizabeth LLC
Actavis Pharma, Inc.
Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, LLC
Aurobindo Pharma USA, Inc.
Bausch Health Americas, Inc.
Bausch Health, US LLC
Fougera Pharmaceuticals, Inc.
G&W Laboratories, Inc.
Glenmark Pharmaceuticals Inc., USA
Greenstone LLC
Lannett Company, Inc.
Lupin Pharmaceuticals, Inc.
Mallinckrodt Inc.
Mallinckrodt plc
Mallinckrodt LLC
Mylan Inc.
Mylan Pharmaceuticals Inc.
Perrigo New York, Inc.
Pfizer, Inc.
Sun Pharmaceutical Industries, Inc.
Taro Pharmaceuticals USA, Inc.
Teligent, Inc.
Wockhardt USA, LLC
Individual Defendants:
Ara Aprahamian, the vice president of sales and marketing at Defendant Taro Pharmaceuticals U.S.A, Inc.
Mitchell Blashinsky, the vice president of marketing for generics at defendant Taro Pharmaceuticals USA, Inc. from January 2007 through May 2012, and vice president of sales and marketing at defendant Glenmark Pharmaceuticals Inc., USA from June 2012 through March 2014.
Douglas Boothe, the chief executive officer of defendant Actavis from August 2008 through December 2012 and the executive vice president and general manager of defendant Perrigo New York, Inc. from January 2013 through July 2016.
James Grauso, the former vice president of sales and marketing at defendant G&W Laboratories from January 2010 through December 2011; the senior vice president, commercial operations for defendant Aurobindo from December 2011 through January 2014; and the executive vice president, N.A. commercial operations at defendant Glenmark from February 2014 to the present.
Walt Kaczmarek, the senior director, national accounts, vice president, national accounts and senior vice president, commercial operations from November 2004 through November 2012 for Fougera Pharmaceuticals, a division of Nycomed US, Inc. (currently part of defendant Sandoz, Inc.), and vice president - general manager, and president, multi-source pharmaceuticals from November 2013 through August 2016 for defendant Mallinckrodt.
Armando Kellum, the former vice president, contracting and business analytics at Sandoz.
Kurt Orlofski, the president and chief executive officer from April 2007 through August 2009 for defendant Wockhardt USA, and president of defendant G&W Labs, Inc. from September 2009 through December 2016.
Mike Perfetto, the vice president of sales and marketing for defendant Actavis from August 2003 through January 2013, and the chief commercial officer for defendant Taro from January 2013 through his recent retirement from the company.
Erika Vogel-Baylor, the former vice president for sales and marketing for defendant G&W Labs, Inc. since July 2011.
John Wesolowski, the senior vice president of commercial operations for defendant perrigo since February 2004.
Drugs listed in the complaint as subject to price-fixing and market allocation agreements:
Man accused of killing wife/ Town holding 4th of July fireworks despite pandemic/ Police sergeant suspects co-workers of vandalism and more.>>>Read More.